Synedgen’s Patent Estate

Synedgen is using its Glycomics Technology Platform (GTP) to develop a new class of healthcare products with the ability to suppress inflammation, reduce infection and improve healing through ultra-purified glycopolymers that enhance and mimic the innate immune system by targeting the cell glycocalyx and mucosal surface.

Synedgen’s GTP and utility are  protected by  a suite of patent families spanning multiple therapeutic targets, including oral health, drug resistant bacterial infections, and inflammation and infection of the pulmonary tree, gastrointestinal tract and eyes.

Synedgen is continuing to expand its glycomics technology patent portfolio to address additional unmet needs in mucosal, dermal, and ophthalmologic health.


Synedgen has licensed its Glycomics Technology for inhaled pulmonary therapeutics to Synspira.